Navigation Links
Drug Shows Dramatic Reduction in Seizures In Patients with Tuberous Sclerosis Complex
Date:7/16/2013

CINCINNATI, July 16, 2013 /PRNewswire-USNewswire/ -- A drug originally developed to prevent the rejection of transplanted organs has now been shown to dramatically reduce seizures in patients with tuberous sclerosis complex (TSC) – a genetic disease characterized by benign tumors on multiple organ systems.  TSC is estimated to affect more than a million individuals throughout the world.

(Logo: http://photos.prnewswire.com/prnh/20110406/MM79025LOGO)

The study is the latest to demonstrate the effectiveness of everolimus for TSC patients. Previous studies conducted at Cincinnati Children's Hospital Medical Center showed that everolimus reduced tumors in the brain and the kidney.

The newest study, led by a physician-scientist at Cincinnati Children's in collaboration with a team at Texas Children's Hospital in Houston, has been accepted by the journal Annals of Neurology, and is available online.

"Everolimus treatment reduced seizure frequency and duration in the majority of TSC epilepsy patients whose seizures previously did not respond to treatment," says Darcy Krueger, MD, PhD, a pediatric neurologist at Cincinnati Children's and lead author of the study.  "This improvement in seizure control was associated with a better quality of life, and side effects were limited.  Work is already underway to confirm these results in a follow-up, phase III clinical study."

"This has been positively life-changing for the patients involved and is nothing short of transformative in the treatment of epilepsy associated with cellular growth disorders, such as TSC," says Angus Wilfong, MD, director of the comprehensive epilepsy program at Texas Children's Hospital and associate professor of pediatrics and neurology at Baylor College of Medicine.

The study included 20 patients who were treated with everolimus. Their median age was 8. Half of the patients were enrolled at Cincinnati Children's and half at Texas Children's Hospital in Houston.

The researchers found that everolimus reduced seizure frequency by at least 50 percent in 12 of the 20 participants.  The drug also reduced seizures in 17 of the 20 TSC patients by a median rate of 73 percent. Four patients were free of seizures and seven had at least a 90 percent reduction in seizure frequency.

Overall quality of life, as reported by the participants' parents, also improved.  Parents reported several positive changes, including attention, behavior, social interaction and physical restrictions.

Studies in the 1990s traced the cause of TSC to defects in two genes, TSC1 and TSC2.  When these genes malfunction, the cell has higher activity of mTOR, a protein known to trigger uncontrolled tumor cell and blood vessel growth.  Everolimus shrinks tumors by inhibiting mTORC1, and it appears to reduce seizures in TSC patients in the same way.

"It is unclear whether the benefit of everolimus in treating epilepsy might extend beyond that observed in TSC," says Dr. Krueger.  "mTORC1 has been implicated in genetic and neurodevelopmental syndromes in which epilepsy is prominent and in more common types of epilepsy.  Additional clinical trials might tell us whether everolimus would benefit patients with epilepsy not related to TSC."

Funding for the study was provided by Novartis Pharmaceuticals and the Clack Foundation.

About Cincinnati Children's

Cincinnati Children's Hospital Medical Center ranks third in the nation among all Honor Roll hospitals in U.S.News and World Report's 2013 Best Children's Hospitals ranking. It is ranked #1 for cancer and in the top 10 for nine of 10 pediatric specialties. Cincinnati Children's is one of the top two recipients of pediatric research grants from the National Institutes of Health, and a research and teaching affiliate of the University of Cincinnati College of Medicine.  The medical center is internationally recognized for improving child health and transforming delivery of care through fully integrated, globally recognized research, education and innovation. Additional information can be found at www.cincinnatichildrens.org. Connect on the Cincinnati Children's blog, via Facebook and on Twitter.


'/>"/>
SOURCE Cincinnati Children's Hospital Medical Center
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Clinical Trial at Evergreen Healthcare Shows Intestinal Gel Reduces Symptoms of Advanced Parkinsons Disease
2. Structural Trends to Profoundly Change Life Sciences Industry, Genpact Study Shows
3. Upsher-Smith Research Shows Unique Pharmacokinetic Profile of USL255 Extended Release Topiramate
4. Survey Shows eContent Critical to Corporate Strategies
5. New Forecast Shows Patient Monitoring Systems Market to Reach $18.9 billion by 2016
6. New Forecast Shows Global Protein Therapeutics Market to Reach $143.4 Billion by 2015
7. Study Shows NxStage Daily Home Hemodialysis Patients More Likely to Receive Kidney Transplant
8. Study of First-in-Class WATCHMAN® Device Shows 75 Percent Reduction in Stroke Risk in Patients with Atrial Fibrillation Not Eligible for Oral Anticoagulation Therapy
9. Medical Device Recalls Soar During First Quarter, ExpertRECALL Index Shows
10. New Study Shows Long-Term Effects of Drug Prevention
11. Large-Scale Meta-Analysis Shows Age Not a Social Barrier to Opioid Use and Misuse
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/12/2017)... , Sept. 12, 2017  Consumer reviews on the independent ... as the number one company for hearing aids, ranking it ... fifteen other brands. ... Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides high performance, ...
(Date:9/9/2017)... 9, 2017  Eli Lilly and Company (NYSE: ... endpoint data for lasmiditan, an investigational, oral, first-in-class molecule ... significant improvements compared to placebo in the Phase 3 ... the 18th Congress of the International Headache Society (IHC) ... data presented today demonstrate lasmiditan,s potential to reduce pain ...
(Date:9/7/2017)... NuvoAir (formerly called Pond Healthcare Innovation), the company commercializing ... Pharma AG to distribute NuvoAir,s spirometry technology to physicians worldwide. ... platform and Novartis, commitment to address the unmet medical needs ... ... "We are ...
Breaking Medicine Technology:
(Date:9/20/2017)... ... September 20, 2017 , ... FirstAlign ( http://www.firstalign.com ), ... latest Artificial Intelligence (AI) thinking, announced today the launch of its revamped web ... essential information that offers a more comprehensive understanding of the organization’s business and ...
(Date:9/20/2017)... ... September 20, 2017 , ... On Thursday, the Triangle ... Work in the Research Triangle for 2017. , Winners were chosen based on ... meet a threshold in employee participation--a percentage that varies based upon the size ...
(Date:9/20/2017)... ... September 20, 2017 , ... Doctors on Liens has added ... network of medical professionals working on a personal injury lien basis. Founded by Dr. ... brings these esteemed doctors’ vast experience with orthopedic injuries to patients in the Inland ...
(Date:9/20/2017)... ... 2017 , ... Mirror Mirror Beauty Boutique is excited to ... Autumn with CoolSculpting®. Scheduled for Thursday, September 28th, the afternoon will include live ... Boutique is Houston’s largest CoolSculpting provider, holding the prestigious title of ...
(Date:9/20/2017)... ... September 20, 2017 , ... Announced that ... clinical and commercial support services market) has entered into an agreement on September ... , The PGSD is the first private Dental School to launch an ...
Breaking Medicine News(10 mins):